Effect of surfactant pluronic F-68 on CHO cell growth, metabolism, production, and glycosylation of human recombinant IFN-γ in mild operating conditions

Biotechnology Progress

Volumn 27, Issue 1, 2011, Pages 181-190

  Clincke, Marie Françoise ^a,b,c   Guedon, Emmanuel ^a   Yen, Frances T ^b   Ogier, Virginie ^c   Roitel, Olivier ^c   Goergen, Jean Louis ^d  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Genclis SAS   (France)

^d CNRS   (France)

Author keywords

CHO; Glycosylation; IFN ; Kinetics; Pluronic F 68 (PF 68)

Indexed keywords

CARBON SUBSTRATES; CELL DENSITY; CELL LYSIS; CHO; CHO CELL; CULTURE MEDIUM; DIFFERENT PROCESS; DOSE-DEPENDENT; GLOBAL KINETICS; GLYCOFORMS; GLYCOSYLATED; HIGHER EFFICIENCY; LAG PHASE; MILD OPERATING CONDITIONS; N-GLYCOSYLATION SITES; PLURONICS; PRODUCT QUALITY; PROTEIN-FREE; QUALITY CONSISTENCY; RECOMBINANT GLYCOPROTEINS; RECOMBINANT PROTEIN; REGULATORY REQUIREMENTS; SPECIFIC PRODUCTION RATE;

ANIMAL CELL CULTURE; CELL DEATH; CELL GROWTH; ESTERIFICATION; GLYCOPROTEINS; GLYCOSYLATION; GROWTH KINETICS; METABOLISM; NONIONIC SURFACTANTS; PHYSIOLOGY; PROTEINS;

CELL CULTURE;

GAMMA INTERFERON; POLOXAMER; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CELL DIVISION; CHO CELL; CRICETULUS; DRUG EFFECT; GLYCOSYLATION; HAMSTER; HUMAN; METABOLISM;

ANIMALS; CELL DIVISION; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOSYLATION; HUMANS; INTERFERON-GAMMA; POLOXAMER; RECOMBINANT PROTEINS;

EID: 79851488185     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.503     Document Type: Article

References (66)

1. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008; 3: 90-97.
2. PhRMA, Washington, DC. Biotechnology Research Continues to Bolster Arsenal Against Disease with 633 Medicines in Development. Washington, 2008. Available at.
3. Matasci M, Hacker DL, Baldi L, Wurm FM. Recombinant therapeutic protein production in cultivated mammalian cells: current status and future prospects. Drug Discov Today: Technol. 2009; 5: 37-42.
4. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotech. 2004; 22: 1393-1398.
5. Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol. 2005; 68: 283-291.
6. Shields R, Lai J, Keck R, O'Connell L, Hong K, Meng Y, Weikert S, Presta L. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002; 277: 26733-26740.
7. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2005; 21: 11-16.
8. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in-vivo potency than recombinant human erythropoietin. Exp Hematol. 2003; 31: 290-299.
9. Wyss D, Wagner G. The structural role of sugars in glycoproteins. Curr Opin Biotechnol. 1996; 7: 409-416.
10. Schmidt FR. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol. 2004; 65: 363-372.
11. Lamotte D. Production et glycosylation de l'interféron-gamma humain par des cellules CHO cultivées en bioréacteurs discontinus et perfusés. Influence des conditions opératoires et du potentiel de glycosylation des cellules. PhD Thesis, Institut National Polytechnique de Lorraine (INPL), Nancy, 1997.
12. Goldman MH, James DC, Rendall M, Ison AP, Hoare M, Bull AT. Monitoring recombinant human interferon-gamma N-glycosylation during perfused fluidized-bed and stirred-tank batch culture of CHO cells. Biotechnol Bioeng. 1998; 60: 596-607.
13. Nyberg GB, Balcarcel RR, Follstad BD, Stephanopoulos G, Wang DIC. Metabolic effects on recombinant interferon-γ glycosylation in continuous culture of Chinese hamster ovary cells. Biotechnol Bioeng. 1999; 62: 336-347.
14. Borys MC, Linzer DI, Papoutsakis ET. Culture pH affects expression rates and glycosylation of recombinant mouse placental lactogen proteins by Chinese hamster ovary (CHO) cells. Nat Biotechnol. 1993; 11: 720-724.
15. Jenkins N, Castro P, Menon S, Ison A, Bull A. Effect of lipid supplements on the production and glycosylation of recombinant interferon-γ expressed in CHO cells. Cytotechnology. 1994; 15: 209-215.
16. Yang M, Butler M. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog. 2002; 18: 129-138.
17. Ferrari J, Gunson J, Lofgren J, Krummen L, Warner TG. Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with increased sialic acid. Biotechnol Bioeng. 1998; 60: 589-595.
18. Rinderknecht E, O'Connor BH, Rodriguez H. Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. J Biol Chem. 1984; 259: 6790-6797.
19. Mutsaers JHGM, Kamerling JP, Devos R, Guisez Y, Fiers W, Vliegenthart JFG. Structural studies of the carbohydrate chains of human γ-interferon. Eur J Biochem. 1986; 156: 651-654.
20. Nienow AW. Reactor engineering in large scale animal cell culture. Cytotechnology. 2006; 50: 9-33.
21. Van der Pol L, Tramper J. Shear sensitivity of animal cells from a culture-medium perspective. Trends Biotechnol. 1998; 16: 323-328.
22. Ahmed F, Alexandridis P, Neelamegham S. Synthesis and application of fluorescein-labeled pluronic block copolymers to the study of polymer-surface interactions. Langmuir. 2001; 17: 537-546.
23. Murhammer DW, Goochee CF. Structural features of nonionic polyglycol polymer molecules responsible for the protective effect in sparged animal cell bioreactors. Biotechnol Prog. 1990; 6: 142-148.
24. Ghebeh H, Gillis J, Butler M. Measurement of hydrophobic interactions of mammalian cells grown in culture. J Biotechnol. 2002; 95: 39-48.
25. Kabanov AV, Alakhov VY. Pluronic Block Copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002; 19: 1-72.
26. Meier SJ, Hatton TA, Wang DIC. Cell death from bursting bubbles: role of cell attachment to rising bubbles in sparged reactors. Biotechnol Bioeng. 1999; 62: 468-478.
27. Michaels JD, Nowak JE, Mallik AK, Koczo K, Wasan DT, Papoutsakis ET. Analysis of cell-to-bubble attachment in sparged bioreactors in the presence of cell-protecting additives. Biotechnol Bioeng. 1995; 47: 407-419.
28. Chattopadhyay D, Rathman JF, Chalmers JJ. The protective effect of specific medium additives with respect to bubble rupture. Biotechnol Bioeng. 1995; 45: 473-480.
29. Jordan M, Sucker H, Einsele A, Widmer F, Eppenberger HM. Interactions between animal cells and gas bubbles: the influence of serum and Pluronic F-68 on the physical properties of the bubble surface. Biotechnol Bioeng. 1994; 43: 446-454.
30. Dey D, Boulton-Stone JM, Emery AN, Blake JR. Experimental comparisons with a numerical model of surfactant effects on the burst of a single bubble. Chem Eng Sci. 1997; 52: 2769-2783.
31. Ramirez OT, Mutharasan R. The role of the plasma membrane fluidity on the shear sensitivity of hybridomas grown under hydrodynamic stress. Biotechnol Bioeng. 1990; 36: 911-920.
32. Michaels JD, Petersen JF, McIntire LV, Papoutsakis ET. Protection mechanisms of freely suspended animal cells (CRL 8018) from fluid-mechanical injury. Viscometric and bioreactor studies using serum, pluronic F68 and polyethylene glycol. Biotechnol Bioeng. 1991; 38: 169-180.
33. Murhammer DW, Goochee CF. Scaleup of insect cell cultures: protective effects of pluronic F-68. Bio/Technology. 1988; 6: 1411-1418.
34. Bentley PK, Gates RMC, Lowe KC, de Pomerai DI, Walker JAL. In-vitro cellular responses to a non-ionic surfactant, Pluronic F-68. Biotechnol Lett. 1989; 11: 111-114.
35. Mizrahi A. Pluronic polyols in human lymphocyte cell line cultures. J Clin Microbiol. 1975; 2: 11-13.
36. Hokett SD, Cuenin MF, O'Neal RB, Brennan WA, Strong SL, Runner RR, McPherson JC, Van Dyke TE. Pluronic polyol effects on human gingival fibroblast attachment and growth. J Periodontol. 2000; 71: 803-809.
37. Gigout A, Buschmann MD, Jolicoeur M. The fate of Pluronic F-68 in chondrocytes and CHO cells. Biotechnol Bioeng. 2008; 100: 975-987.
38. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem. 1985; 54: 631-664.
39. Paulson JC, Colley KJ. Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J Biol Chem. 1989; 264: 17615-17618
40. Allen S, Naim HY, Bulleid NJ. Intracellular folding of tissue-type plasminogen activator. Effects of disulfide bond formation on N-linked glycosylation and secretion. J Biol Chem. 1995; 270: 4797-4804.
41. Holst B, Bruun AW, Kielland-Brandt MC, Winther JR. Competition between folding and glycosylation in the endoplasmic reticulum. EMBO J. 1996; 15: 3538-3546.
42. Shelikoff M, Sinskey AJ, Stephanopoulos G. A modeling framework for the study of protein glycosylation. Biotechnol Bioeng. 1996; 50: 73-90.
43. Kochanowski N, Blanchard F, Cacan R, Chirat F, Guedon E, Marc A, Goergen J-L. Influence of intracellular nucleotide and nucleotide sugar contents on recombinant interferon-γ glycosylation during batch and fed-batch cultures of CHO cells. Biotechnol Bioeng. 2008; 100: 721-733.
44. Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009; 19: 936-949.
45. Monaco L, Tagliabue R, Soria MR, Uhlen M. An in-vitro approach for the expression of recombinant proteins in mammalian cells. Biotechnol Appl Biochem. 1994; 20: 157-171.
46. Bragonzi A, Distefano G, Buckberry LD, Acerbis G, Foglieni C, Lamotte D, Campi G, Marc A, Soria MR, Jenkins N, Monaco L. A new Chinese hamster ovary cell line expressing α2, 6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. Biochim Biophys Acta. 2000; 1474: 273-282.
47. Schneider Y-J. Optimization of hybridoma cell growth and monoclonal antibody secretion in chemically defined serum- and protein-free medium. J Immunol Methods. 1989; 116: 67-77.
48. Rodríguez Ninño MR, Rodríguez Patino JM. Surface tension of protein and insoluble lipids at the air-aqueous phase interface. J Am Oil Chem Soc. 1998; 75: 1233-1239.
49. Nielsen LK, Smythl GK, Greenfield PF. Hemacytometer cell count distributions: implications of non-poisson behavior. Biotechnol Prog. 1991; 7: 560-563.
50. Goergen JL, Marc A, Engasser JM. Determination of cell lysis and death kinetics in continuous hybridoma cultures from the measurement of lactate dehydrogenase release. Cytotechnology. 1993; 11: 189-195.
51. Mols J, Burteau CC, Verhoeye FR, Ballez JS, Agathos SN, Schneider YJ. Fortification of a protein-free cell culture medium with plant peptones improves cultivation and productivity of an interferon-γ producing CHO cell line. In Vitro Cell Dev Biol Anim. 2003; 39: 291-296.
52. Butler M. Mammalian Cell Biotechnology: a Practical Approach. Oxford: Oxford University Press; 1991.
53. Xu D, Wu T, Wu X, Zhang Y, Chen Y. Studies of protective properties of Pluronic and other agents on the hybridoma cell culture. Chin J Biotechnol. 1995; 11: 101-107.
54. Zhang Z, Al-Rubeai M, Thomas CR. Effect of Pluronic F-68 on the mechanical properties of mammalian cells. Enz Microb Technol. 1992; 14: 980-983.
55. Passini CA, Goochee CF. Response of a mouse hybridoma cell line to heat shock, agitation, and sparging. Biotechnol Prog. 1989; 5: 175-188.
56. Keen MJ, Rapson NT. Development of a serum-free culture medium for the large scale production of recombinant protein from a Chinese hamster ovary cell line. Cytotechnology. 1995; 17: 153-163.
57. Tharmalingam T, Ghebeh H, Wuerz T, Butler M. Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol Biotechnol. 2008; 39: 167-177.
58. Katakam M, Banga AK. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharm Dev Technol. 1997; 2: 143-149.
59. Laouar L, Lowe KC, Mulligan BJ. Yeast responses to nonionic surfactants. Enz Microb Technol. 1996; 18: 433-438.
60. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008; 130: 98-106.
61. Kabanov A, Batrakova E, Alakhov V. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002; 82: 189-212.
62. Kabanov AV, Vinogradov SV, Suzdaltseva YG, Alakhov V. Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug Chem. 1995; 6: 639-643.
63. Torchilin VP. Structure and design of polymeric surfactant-based drug delivey systems. J Control Release. 2001; 73: 137-172.
64. Kato Y, Hiraoka S, Tada Y, Koh ST, Lee YS. Mixing time and power consumption for a liquid in a vertical cylindrical vessel, shaken in a horizontal circle. Chem Eng Res Des. 1996; 74: 451-455.
65. Busto VD, Rodríguez-Talou J, Giulietti AM, Merchuk JC. Effect of shear stress on anthraquinones production by Rubia tinctorum suspension cultures. Biotechnol Prog. 2008; 24: 175-181.
66. Suresh S, Srivastava VC, Mishra IM. Critical analysis of engineering aspects of shaken flask bioreactors. Crit Rev Biotechnol. 2009; 29: 255-278.